COMPASS THERAPEUTICS (CMPX)
Health Care · biotechnology · NASDAQ
Clinical-stage biopharma company developing next-generation bispecific and agonistic antibody therapies targeting angiogenesis and the tumor microenvironment to treat solid tumors.
What COMPASS THERAPEUTICS does
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. Its research focus centers on the relationship between angiogenesis, the immune system, and tumor growth, with a pipeline designed to target multiple biological pathways for an effective anti-tumor response. The company's lead product candidate is a bispecific antibody for biliary tract cancer, and it maintains a diversified portfolio of clinical-stage bispecific and agonistic antibodies.
Recent developments
In April 2026, the company reported positive survival and safety data for tovecimig in BTC, meeting primary endpoints and preparing for a potential BLA filing. It also reported clinical updates on its CTX-8371 and CTX-10726 programs and plans to initiate a Phase 2 study of CTX-471 in Q3 2026.
From COMPASS THERAPEUTICS's filing of 2026-08-06.
Themes: oncology, bispecific antibodies, immune-oncology, angiogenesis inhibitors, biliary tract cancer
Fundamentals
- Price$0.9834 as of 2026-10-08 close
- Market cap$177M as of 2026-07-28 (share count; price 2026-10-08)
- 1-year return-74.8% 2025-10-08 close $3.90 → 2026-10-08 close $0.9834
- P/En/a negative earnings
- ROE-33.8% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Beta1.48 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How CMPX compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How COMPASS THERAPEUTICS looks technically
COMPASS THERAPEUTICS (CMPX) is trading 72.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 103 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 54, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 25, in oversold territory (below 30). It made a new 20-day low about 5 trading days ago. It is 85.7% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 72.4% below its 200-day average, the long-term trend line — a long-term downtrend | -72.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.89 | $1.89 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.56 | $3.56 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 44 calendar days ago — the swings before that are what the structure reading is measured on | 44 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 2.55. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 103 trading days ago — a "death cross", a bearish long-term signal | 103 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 54, with sellers in control | 54.2 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 25, in oversold territory (below 30) | 25.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($0.829 to $1.88) — its "stochastic" reading is 15 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 14.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 27 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $6.88 | $6.88 |
|---|---|---|
| From the 52-week high | it is 85.7% below its 52-week high (its highest price of the past year) | -85.7% |
| Above the 52-week low | it is 18.6% above its 52-week low (its lowest price of the past year) | +18.6% |
| Below the 52-week high | it is 85.7% below its highest point of the past year | 85.7% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $11.00 (set on 2021-04-16) | $11.00 |
| Given back of the 52-week move | over the past year its closes ranged ($0.857 to $6.69), and it has recovered only a small part of its fall from last year’s high — 2% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.46 to $4.65. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 2.2% |
| From the all-time high | it is 91.1% below its all-time high | -91.1% |
| Nearest price level | it is trading 35.3% below a resistance level at $1.33 — a price it turned at twice since 2024-12-19, most recently on 2025-04-01. Since 2024-10-08 it has 0 such levels below the current price and 14 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +35.3% |
| All-time low | its lowest closing price on record is $0.765 (set on 2024-07-05) | $0.765 |
| Above the all-time low | it is 28.5% above its all-time low | +28.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 83% of the past ~6 months) | 83rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.121 between its high and its low — about 12.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.121 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.52 and $2.16 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.52 – $1.34 – $2.16 |
| Typical daily range (% of price) | its price moves about 12.3% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 12.3% |
| Stretch from the 200-day average | it is trading 21.3 daily ranges below its 200-day average price (72.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 21.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.29× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.8% since the prior reading | -0.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.0% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -1.0% |
|---|---|---|
| Open gap | it gapped 6.2% above the previous close 3 sessions ago and has not traded back through the level it left behind at 0.86 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.2% |
| Gap filled | a 3.0% gap up opened on 2026-10-06 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 56.5 percentage points (the stock lost 55.5% while the market gained 1.0%) | -56.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 61.8 percentage points (the stock lost 58.0% while the market gained 3.8%) | -61.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 99.5 percentage points (the stock lost 82.1% while the market gained 17.5%) | -99.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 89.8 percentage points (the stock lost 74.8% while the market gained 15.0%) | -89.8% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 55% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 11.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -55.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 62% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.62 — a volume-weighted average of daily closes over 192 sessions, not a true tick-by-tick VWAP. | -62.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 37% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $1.56 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -37.2% |
Price levels it has turned at before
CMPX last closed at $0.9834 on 2026-10-08. Since 2024-10-08 it has turned at 0 prices below its last close and 14 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.33 | Resistance | 35.3% above the last close | turned there twice · 2024-12-19 to 2025-04-01 |
| $2.01 | Resistance | 104.4% above the last close | turned there twice · 2024-11-11 to 2026-05-14 |
| $2.15 | Resistance | 119.1% above the last close | turned there twice · 2025-06-17 to 2026-06-17 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $2.55.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 27 trading days, since 2026-09-01.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · lagging the market · Left an unfilled gap (5%+ in the last week) · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.53 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$5.45 range $1.00 – $12.00; median $6.00
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CMPX
- Consensus EPS estimate-$0.1264 next reporting period, as of 2026-10-07
- Estimate change, 30 days+$0.00182 from -$0.1282, on 2026-09-03, 34-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["No approved products for commercial sale and history of operating losses.","High capital requirements and need for future financing to sustain long-term operations.","Risks associated with the clinical trial process, regulatory approvals, and potential failure of product candidates."]
What changed in the latest 10-Q
AI-assisted comparison of CMPX's 10-Q filed 2026-08-06 against the prior one filed 2026-05-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-06) adds 'Recent Developments' subsection 'Tovecimig Investigator Sponsored Trials' describing the ongoing IST (NCT06548412) expansion to additional sites and two newly initiated ISTs: tovecimig plus FOLFIRI in colorectal cancer (NCT07662031) and tovecimig plus CTX-471 in glioblastoma (NCT07392957), plus evaluation of additional studies.
- Newer filing (2026-08-06) adds 'Recent Developments' subsection 'CTX-8371 (PD-1 x PD-L1 bispecific) Phase 1 Expansion Cohorts Enrolling' describing active enrollment in TNBC, HL, and NSCLC at 3.0 mg/kg and 10.0 mg/kg dose levels, RP2D evaluation, expected additional cohort expansion data in Q4 2026, and ASCO May 2026 dose-escalation data including 15 DLT-evaluable patients, three responses, ORR of 33% at the two highest dose levels, response durations, and safety findings.
- Newer filing (2026-08-06) adds 'Recent Developments' subsection 'CTX-10726 (PD-1 x VEGF-A bispecific) Phase 1 Dose-Escalation Study Enrolling' stating first patients dosed in Phase 1 with renal cell carcinoma, gastroesophageal cancer, hepatocellular carcinoma, or endometrial cancer, and clinical data expected in Q4 2026.
- Newer filing (2026-08-06) states the final ORR improved to 18.0% (20/111 patients) from previously reported 17.1%, with one patient re-adjudicated to partial response and p-value improved to 0.0228 (vs 0.031).
- Newer filing (2026-08-06) states the COMPANION-002 study is a Phase 2/3 randomized trial named COMPANION-002.
- Newer filing (2026-08-06) states overall survival analysis was confounded by high crossover (54%) and notably prolonged survival in crossover patients, and therefore did not meet statistical significance.
- Newer filing (2026-08-06) adds July 2026 announcement that COMPANION-002 data was selected for a proffered paper oral presentation at the 2026 ESMO Congress.
- Newer filing (2026-08-06) expects FDA feedback in Q3 2026 regarding COMPANION-002 data prior to a potential BLA filing later this year.
- Newer filing (2026-08-06) includes one complete response in the tovecimig combination arm when describing the ORR of 18.0%.
- Removed:
- Older filing (2026-05-05) includes detailed April 2026 secondary endpoint data: OS median of 8.9 months for tovecimig arm, PFS before/after crossover (PFS2 3.5 months vs PFS1 1.9 months, HR=0.36, p=0.0016), OS crossover vs non-crossover (12.8 vs 6.1 months, HR=0.54, p=0.04), pooled OS of all tovecimig-treated patients (9.8 months) vs non-crossover control (6.1 months), and safety statement that tovecimig was generally well tolerated with no new safety signals.
- Older filing (2026-05-05) includes the statement that tovecimig received Orphan Drug Designation from the FDA in April 2026 for BTC, including associated development incentives and seven years of market exclusivity upon approval.
- Older filing (2026-05-05) includes the sentence 'We intend to meet with the U.S. Food and Drug Administration (“FDA”) to discuss these data in advance of a planned BLA submission.'
- Older filing (2026-05-05) includes a mislabeled date: 'In April 2025, we announced that the study met its primary endpoint...' where the context indicates the announcement relates to the same study previously reported in April 2026.
- Older filing (2026-05-05) states the study achieved a 17.1% ORR with statistical significance (p=0.031), which is replaced in the newer filing with 18.0% and p=0.0228.
- Reworded:
- Newer filing (2026-08-06) changes the introductory paragraph from 'for the three months ended March 31, 2026' to 'for the three and six months ended June 30, 2026'.
- Newer filing (2026-08-06) changes 'CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9)' to 'CTX-471 is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily (TNFRSF9)'.
- Newer filing (2026-08-06) changes 'CTX-8371, is a bispecific antibody' to 'CTX-8371 is a bispecific antibody'.
- Newer filing (2026-08-06) changes 'targeting PD-1 and VEFG-A' to 'targeting PD-1 and VEGF-A'.
- Newer filing (2026-08-06) changes the Recent Developments heading for tovecimig from 'Tovecimig results in Phase 2/3 Study in the Second Line Setting for Patients with BTC' to 'Tovecimig Results in COMPANION-002 Phase 2/3 Study in the Second Line Setting for Patients with BTC'.
- Newer filing (2026-08-06) changes the April 2026 announcement description from a statement that the primary endpoint was met with 17.1% ORR to a description of survival and safety data with final ORR of 18.0%.
- Newer filing (2026-08-06) changes overall survival description from detailed post hoc subset analyses to a summary noting confounding by crossover and prolonged survival, with OS not meeting statistical significance.
- Newer filing (2026-08-06) changes crossover count from (n=31) to 54% and control arm count from (n=57) consistently removed.
- Newer filing (2026-08-06) adds 'including one complete response in the tovecimig arm' when describing the ORR of 18.0%, versus older filing which mentioned 'including one complete response' with the 17.1% ORR.
- Notes:
- Newer MD&A text is truncated after 'we do not expect to generate any re', so later MD&A subsections could not be compared.
- The older filing contains a possible typo ('In April 2025') for an announcement that context indicates occurred in April 2026; this date discrepancy is reported as written.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
2 open-market purchases and 0 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-042 buys ($21250) · 0 sells — 1 buying insider
- Last 90 days · read to 2026-10-042 buys ($21250) · 0 sells — 1 buying insider
- Last 180 days · read to 2026-10-044 buys ($96850) · 0 sells — 2 buying insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-01. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CMPX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding CMPX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 29,867,578
- Reported value $65,409,995
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CMPX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CMPX had 41,647,512 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CMPX had 23.1% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 15.99 days to cover at the same settlement.
- Reported short interest (shares) 41,647,512
- Short interest (% of shares outstanding) 23.1%
- Prior settlement (shares) 40,788,891
- Reported change 2.11%
- Days to cover (reported) 15.99
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Merck (MRK)
- Bristol Myers Squibb (BMY)
- AstraZeneca (AZN)
- Roche (RHHBY)
- Regeneron Pharmaceuticals (REGN)
- Incyte (INCY)
- Seagen (SGEN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CMPX vs…
COMPASS THERAPEUTICS is found in…
Frequently asked questions
What does COMPASS THERAPEUTICS (CMPX) do?
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. Its research focus centers on the relationship between angiogenesis, the immune system, and tumor growth, with a pipeline designed to target multiple biological pathways for an effective anti-tumor response.
What sector is COMPASS THERAPEUTICS (CMPX) in?
COMPASS THERAPEUTICS (CMPX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are COMPASS THERAPEUTICS's (CMPX) competitors?
Notable peers of COMPASS THERAPEUTICS (CMPX) include Merck, Bristol Myers Squibb, AstraZeneca, Roche and Regeneron Pharmaceuticals. This peer set is informational only — not financial advice.
Is COMPASS THERAPEUTICS (CMPX) overbought or oversold right now?
COMPASS THERAPEUTICS (CMPX) is currently in oversold territory (its 14-day RSI is 25, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CMPX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.